# Rivus Pharmaceuticals

> Rivus Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company developing
> oral small-molecule medicines for obesity and associated cardio-metabolic disease. Its work is
> grounded in mitochondrial biology — controlled metabolic accelerators that increase energy
> expenditure to reduce fat mass while preserving lean mass. Rivus does not run a developer program
> and publishes no API.

<!--
generated: 2026-08-05
method: generated
source: apis.yml + live probes of rivuspharma.com on 2026-08-05
note: Generated by the API Evangelist enrichment pipeline. Rivus Pharmaceuticals does not publish an
      llms.txt of its own — https://www.rivuspharma.com/llms.txt returns HTTP 404.
-->

## About

Rivus Pharmaceuticals was founded in 2019. Its named co-founders are Allen Cunningham (Chief
Operating Officer), Shaharyar Khan, Ph.D. (Chief Scientific Officer) and Francisco Portell (Vice
President, Pharmaceutical Development) — all three previously co-founded Gencia Biotech. Its
corporate office is at 701 Gateway Blvd, Suite 300, South San Francisco, CA 94080, with research
operations at 501 Locust Ave., Suite 301, Charlottesville, VA 22902. Jorge Bartolome is Chief
Executive Officer. David Grainger, Ph.D. of Medicxi is Co-Chair of the Board. The company closed a
$132 million Series B in September 2022, led by RA Capital Management with Bain Capital Life
Sciences, BB Biotech and returning investors Longitude Capital, Medicxi and RxCapital participating.

## Pipeline

- **HU6** — an oral controlled metabolic accelerator (mitochondrial uncoupler) in Phase 2 development
  for metabolic dysfunction-associated steatohepatitis (MASH). The Phase 2 AMPLIFY trial is
  enrolling; the earlier Phase 2 M-ACCEL trial reported significant reductions in liver fat, and the
  Phase 2a HuMAIN trial reported weight loss in obesity-related heart failure with preserved
  ejection fraction (HFpEF), published in JAMA Cardiology. Approximately 450 patients have received
  HU6 across the clinical development program.
- **RV-8451** — an oral non-peptide GLP-1 receptor agonist for obesity, positioned as
  muscle-preserving, in IND-enabling studies.

## Site

- [Home](https://www.rivuspharma.com/)
- [About](https://www.rivuspharma.com/about/): management team, board of directors, investors
- [Our Focus — MASH](https://www.rivuspharma.com/our-focus/mash/)
- [Our Focus — Obesity](https://www.rivuspharma.com/our-focus/obesity/)
- [Our Pipeline](https://www.rivuspharma.com/our-pipeline/)
- [News](https://www.rivuspharma.com/news/): press releases, publications and relevant literature
- [Careers](https://www.rivuspharma.com/careers/)
- [Privacy](https://www.rivuspharma.com/privacy/)
- [Terms](https://www.rivuspharma.com/terms/)
- [LinkedIn](https://www.linkedin.com/company/rivus-pharmaceuticals)

## APIs

Rivus Pharmaceuticals publishes no API. As of 2026-08-05 there is no developer portal, no API
documentation, no SDK, no OpenAPI/Swagger/AsyncAPI/GraphQL contract, no Postman collection, no MCP
server and no A2A agent card. No `api.`, `developer.`, `docs.`, `portal.`, `app.`, `status.`,
`trust.`, `data.` or `partners.` host resolves for rivuspharma.com, and no Rivus GitHub organisation
exists under any plausible name. Every `/.well-known/` discovery path and every spec-discovery path
returns a genuine HTTP 404 on both the apex and the www host.

Note for agents: an npm package named `rivus-sdk` exists, but it is an unrelated TypeScript SDK for
Rivus payment-streaming contracts on the Stacks blockchain. It is not published by, affiliated with,
or a client for Rivus Pharmaceuticals.

## API Evangelist profile

- [apis.yml](https://raw.githubusercontent.com/api-evangelist/rivus-pharmaceuticals/refs/heads/main/apis.yml)
- [Well-known / discovery probe results](https://raw.githubusercontent.com/api-evangelist/rivus-pharmaceuticals/refs/heads/main/well-known/rivus-pharmaceuticals-well-known.yml)
- [Domain security probe](https://raw.githubusercontent.com/api-evangelist/rivus-pharmaceuticals/refs/heads/main/security/rivus-pharmaceuticals-domain-security.yml)